National Cancer Institute, Research Contracts Branch, Purchasing and Support Contracts Section, EPS/638, 6120 EXECUTIVE BLVD MSC 7228, BETHESDA MD 20892-7228

65 -- SYMPHONY MULTIPLEX PEPTIDE SYNTHESIZER SOL N02-CB-56247-81 POC Janet Mattson, Contracting Officer, 301/402-4509. The National Cancer Institute (NCI), Division of Cancer, Biology, Diagnosis and Centers (DCBDC), Metabolism Branch, Molecular Immunogenetics and Vaccine Research Section (MIVRS), plans to procure on a SOLE SOURCE basis under authority of FAR 6.320-1, in accordance with 41 U.S.C. 253(c)(1), a Symphony Multiplex Peptide Synthesizer from Rainin Instrument Co. It is essential that the MIVRS purchase a Symphony Multiplex Peptide Synthesizer in order to meet their specific needs for several research projects. In order to meet the needs of their research projects, the system must have the following minimum essential characteristics: The system must have at least 12 reaction vessels that allow for the synthesis of 12 peptides simultaneously. The system must be capable of performing 12 different coupling protocols simultaneously which allows proper synthesis of any one peptide according to its unique synthesis characteristics. The system must have liquid sensors which act as a safety feature to protect against potential fluid transfer problems and empty solvent or reagent containers. The system must be capable of simultaneous solution transfer via a matrix valve which allows any reaction vessel to simultaneously get the same or different solution transferred to or from the vessel on different time bases. Cleavage must be performed via a fully automated cleavage system incorporated into the instrument. The instrument must measure delivered volumes of reagent via a sample loop in order to ensure accurate delivery of reagents. Syntheses must be accomplished completely independent from each other in order to synthesize only the peptides currently needed, with the ability to start others when additional orders are placed. Agitation must be done via nitrogen in order to ensure better coupling efficiencies in a efficient manner. Solutions must be transferred by nitrogen in order to ensures that the coupling occurs in an inert N2 atmosphere. The system must permit use of standard pre-programmed FMOC protocols or customized reaction protocols for each individual synthesis. Prepackaged reagents must be available in large or small quantities. The system must be able to be used as a conventional synthesizer with larger scale operation possible to at least 0.1mM or higher depending on length of peptide and substitution of resin. The length of the peptide should not be a limiting factor. The system must be able to be used with standard existing lab ventilation systems which allows the use of standard available hoods without modifications or additional booster fans. It is the Government's belief that the above requirements can only be met by Rainin Instrument Co. This notice of intent is not a request for competitive proposals, however, if an interested party believes they can meet the above listed minimum essential characteristics, they may submit a statement of capabilities. Information furnished shall include enough material, in sufficient detail to perform a proper evaluation of their ability to meet the characteristics. Closing date is 45 days after publication of this notice. SEE Note 22. (0156)

Loren Data Corp. http://www.ld.com (SYN# 0368 19950606\65-0001.SOL)